Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials

Pediatric Blood and Cancer

Volumn 47, Issue 1, 2006, Pages 42-50

  Eselgrim, Merle ^a   Grunert, Henrike ^a   Kühne, Thomas ^b   Zoubek, Andreas ^c   Kevric, Matthias ^a   Bürger, Horst ^a   Jürgens, Herbert ^a   Mayer Steinacker, Regine ^d   Gosheger, Georg ^a   Bielack, Stefan S ^a,e  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e OLGAHOSPITAL   (Germany)

Author keywords

Chemotherapy; Dose intensity; Osteosarcoma

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFANT; LIMB TUMOR; MAJOR CLINICAL STUDY; MALE; NEWBORN; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; IFOSFAMIDE; INFANT; MALE; METHOTREXATE; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33646889372     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20608     Document Type: Article

References (68)

1. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. Review article. N Engl J Med 1999;341:342-352.
2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.
3. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
4. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988;6:329-337.
5. Saeter G, Alvegard TA, Ilomaa I, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: A Scandinavian Sarcoma Group study. J Clin Oncol 1991;9:1766-1775.
6. Marina N, Gebhardt M, Teot L, et al. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422-741.
7. Winkler K, Bielack SS. Chemotherapy in osteosarcoma. Sem Orthop 1988;13:48-58.
8. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
9. Cardoso AA, Ferreira CG, Mendes GQ. High dose ifosfamide for metastatic osteosarcoma: Report on 27 patients. Proc Am Soc Clin Oncol 2003;22:829 (abstr. 3331).
10. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-1230.
11. Uchida A, Myoui A, Araki N, et al. Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer 1997;79:411-415.
12. Bielack S, Machatschek JN, Flege S, et al. Delaying surgery with chemotherapy for osteosarcoma of the extremities. Expert Opin Pharmacother 2004;5:1243-1456.
13. Bielack SS, Kempf-Bielack B, Schwenzer D, et al. Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremitäten-Erfahrungen der Cooperativen Osteosarkomstudiengruppe COSS an 925 Patienten. Klin Pädiatr 1999;211:260-270.
14. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-1606.
15. Bacci G, Ferrari S, Linghi A, et al. Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Oncol Rep 2001;8:883-888.
16. Delepine N, Delepine G, Bacci G, et al. Influence of methotrexate dose intensity on outcome of patients with high-grade osteogenetic osteosarcoma-Analysis of the literature. Cancer 1996:78:2127-2135.
17. Lewis IJ, Weeden S, Machin D, et al. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. J Clin Oncol 2000;18:4028-4037.
18. Smith MA, Ungerleider RS, Horowitz ME, et al. Influence of doxorubicin dose intensity on response and outcome with osteogenetic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991;83: 1460-1470.
19. Crews KR, Liu T, Rodiguez-Galindo C, et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 2004;100:1724-1733.
20. Tannock IF, Boyed NF, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988;6:1377-1387.
21. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensitiy in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-977.
22. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991;9:499-508.
23. Focan C, Andrien JM, Closon MT, et al. Dose-response of epirubicin based first-line chemotherapy for advanced breast cancer. A prospective randomized trial. J Clin Oncol 1993;11: 1253-1263.
24. Schabel F. Concepts of systemic treatments of micrometastases. Cancer 1975;35:15-24.
25. Schabel F, Griswold D, Corbett T. Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer 1984;54:1160-1167.
26. Hryniuk WM, Levine MN, Levin L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr 1986;1:87-94.
27. Sculier JP, Lafitte JJ, Lecompte J, et al. A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. Ann Oncol 2002;13:1454-1459.
28. Sweetenham JW, McKendrick JJ, Jones DH, et al. High dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: Results of a pilot study. Br J Cancer 1990; 61:319-322.
29. Balzarotti M, Spina M, Sarina B, et al. Intensified CHOP regimen in aggressive lymphomas: Maximal dose intensity and dose density of doxorubicin and cyclophosphamide. Ann Oncol 2002;13:1341-1346.
30. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: Results of a Cooperative German/Austrian study. J Clin Oncol 1984;2:617-624.
31. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the cooperative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998;9:893-899.
32. Salzer-Kuntschik M, Brand G, Delling G. Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologie 1983;4:135-141.
33. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990;8:1935-1937.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1983;53:457-481.
35. Mantel M. evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170.
36. Cox DR. Regression models and life-tables. JR Stat Soc 1972;34: 187-220.
37. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities-Results in 164 patients preoperatively treated with high-doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993; 72:3227-3238.
38. Bacci G, Ferrari S, Bertoni F, et al. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy. Clin Orthop Relat Res 2001;186-196.
39. Ferrari S, Bacci G, Picci P, et al. Long-term follow-up and post-relapse survival in patients with nonmetastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 1997;8:765-771.
40. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Ketterin (T12) protocol. J Clin Oncol 1998; 16:2452-2458.
41. Saeter G, Elomaa I, Wahlqvist Y, et al. Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl 1997;273:156-1560.
42. Saeter G, Wiebe T, Wiklund T, et al. Chemotherapy in osteosarcoma-The Scandinavian Sarcoma Group experience. Acta Orthop Scand 1999;70:74-82.
43. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet 1997;350: 911-917.
44. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 1997;12:156-160.
45. Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996;14:848-858.
46. Ferrari S, Bertoni F, Mercuri M, et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 2001;12:1145-1150.
47. Philip T, Iliescu C, Demaille MC, et al. High-dose methotrexate and HELP [Holoxan (ifosfamide), Eldesine (vindesine), platinum]-doxorubicin in non-metastatic osteosarcoma of the extremity: A French multicentre pilot study. Ann Oncol 1999;10:1065-1071.
48. French Bone Tumor Study Group. Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alterning drug combinations and early prophylactic lung irradiation. Cancer 1988;61:1304-1311.
49. Meyers PA, Heller G, Healey J, et al. Chemotherapy for non-metastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
50. Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: Intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol 2003;25:845-853.
51. Tabone MD, Kalifa C, Rodary C, et al. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 1994;12:2614-2620.
52. Leung S, Marshall GM, Al Mahr M, et al. Prognostic significance of chemotherapy dosage characteristics in children with osteogenic sarcoma. Med Pediatr Oncol 1997;28:179-182.
53. Smith M, Abrams J, Trimble E, et al. Dose intensity of chemotherapy for childhood cancers. Oncologist 1996;1:293-304.
54. Alberto P. Intensité de dose en chimiotherapie anticancéreuse: définition, intensité de dose relative moyenne et intensité de dose effectivement reζue. Bull Cancer 1995;82:3s-8s.
55. Bentzen SM. Prognostic factor studies in oncology: Osteosarcoma as a clinical example. Int J Radiat Oncol Biol Phys 2001;49:513-518.
56. Bacci P, Picci P, Avella M, et al. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: A retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively. J Chemother 1990;2:127-135.
57. Takahashi M, Katagiri H, Sato K, et al. The importance of dose intensity in preoperative chemotherapy for osteosarcoma-Retrospective analysis of a short intensive chemotherapy regimen pre-operatively using high-dose methotrexate and cisplatinum. Gan to Kagaku Ryoho 1994;21:459-464.
58. Kawai A, Sugihara S, Kunisada T, et al. The importance of doxorubicine and methotrexate dose intensity in the chemotherapy of osteosarcoma. Arch Orthop Trauma Surg 1996;115:68-70.
59. Zelcer S, Kellick M, Wexler LH, et al. Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 2005;44:638-642.
60. Felgenhauer J, Hawkins D, Pendergrass T, et al. Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas. Med Pediatr Oncol 2000;34:29-38.
61. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23:2004-2011.
62. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972;30:1627-1631.
63. Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses)and intraarterial cisplatin. Cancer 1990;65:2539-2553.
64. Bielack SS, Beron G, Winkler K. Comment on. Cancer 1996;78:2127-2135;
65. Influence of methotrexate dose intensity on outcome of patients with high-grade osteogenetic osteosarcoma-Analysis of the literature. Cancer 1997;80:516-518.
66. Delepine N, Delepine G, Desbois JC. A monocentric therapy study: An approach to optimize the results of the treatment of osteosarcoma by protcols based upon HDMTX, associated with systemic conservative surgery. Cancer Treat Res 1993;62:327-332.
67. Graf N, Winkler K, Betlemovic M, et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994;12: 1443-1451.
68. Lewis I, Nooij M. Chemotherapy at standard or increased dose intensity in patients with operable osteosarcoma of the extremity: A randomized controlled trial of the European Osteosarcoma Intergroup (ISRCTN 86294690). Proc Am Soc Clin Oncol 2003;22:816 (abstr. 3281).